Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BullFrog AI Holdings, Inc. ( (BFRG) ).
In a December 30, 2025 letter to shareholders, BullFrog AI detailed a year of transition from platform development to commercialization, highlighted by deepening discussions with large global pharmaceutical companies on potential out-licensing and discovery research collaborations that could include upfront, milestone, and revenue-sharing components. The company reported a 2025 commercial collaboration with contract research organization Sygnature Discovery, expected to generate meaningful revenue through 2028 by expanding sales of BullFrog Data Networks™, alongside stepped-up internal sales efforts for its clinical trial optimization solutions and bfPREP™, which together leverage validated use cases in oncology and neuroscience. BullFrog AI emphasized the evolution of its technology into a scalable, cloud-agnostic, enterprise-grade stack aimed at recurring relationships with big pharma, and cited scientific validation from its work with Eleison Pharmaceuticals on a late-stage oncology program, which has led to talks on a follow-on project and acceptance of a jointly authored abstract for presentation at the 2026 ASCO GI Cancers Symposium. The launch of bfPREP™, originally developed for Eleison, was presented as strategically important for converting the data-preparation bottleneck into a commercial opportunity by rapidly transforming fragmented data into AI-ready datasets, positioning the firm to engage earlier in the drug development process. Management also underscored its lean annual cash burn of about $6.2 million and access to additional equity financing facilities, arguing that even a single sizeable partnership could materially strengthen its financial profile as it enters 2026 with increased validation, credibility, and a pipeline of potential commercial catalysts.
More about BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc., based in Gaithersburg, Maryland, is a technology-enabled drug development company that uses artificial intelligence and machine learning to support the development of pharmaceuticals and biologics. Its modular, enterprise-grade solutions, including the BullFrog Data Networks™ platform and the bfPREP™ data preparation tool, target major biopharma needs such as data readiness, target discovery, clinical trial optimization, and patient stratification across oncology, neuroscience, rare diseases, and broader real-world data and multi-omics markets.
Average Trading Volume: 218,139
Technical Sentiment Signal: Sell
Current Market Cap: $10.27M
For an in-depth examination of BFRG stock, go to TipRanks’ Overview page.